xmas 2015, page-4

if we have good clinical data by then, then it'd be abnormal not to have at least an equivalent valuation to our nearest competitor - say Alnylam.

that'd be roughly $50 pps.

also, that'd be conservative given alny's good clinical data in far smaller target markets than Benitec's pipeline.

and Cool would be the first person in history to deliver a prediction ahead on time and budget, given he originally forecast 2017.